Navigation Links
Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Date:2/2/2010

EMERYVILLE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).  Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through February 23, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

SOURCE Onyx Pharmaceuticals, Inc.

RELATED LINKS
http://www.onyx-pharm.com

'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
2. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
3. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
4. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
5. Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
6. Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
8. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
11. Poniard Pharmaceuticals Announces $6.5 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Symbios Technologies, Inc. ... the company has engaged in a collaborative research partnership with Colorado State University ... Office of the Vice President for Research. This agreement is designed to further ...
(Date:12/6/2016)... Ind. , Dec. 6, 2016 Zimmer ... "Company") today announced the pricing terms of its ... to $1.25 billion aggregate purchase price (excluding accrued and ... settlement date and excluding fees and expenses related ... the debt securities identified in the table below ...
(Date:12/6/2016)... ... December 06, 2016 , ... RoviSys, a leading ... in Aurora, Ohio, announced the opening of their new office building today. Located ... facility is home to 200 employees focused on providing sales, engineering, and support ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt with Chip ... technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal Gold Soil ... 30 years, Chip Baker other industry veterans have made the evolution of cannabis ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/24/2016)... 23, 2016 Cercacor today introduced Ember TM ... trainers non-invasively measure hemoglobin, Oxygen Content, Oxygen ... Respiration Rate in approximately 30 seconds. Smaller than a ... immediate access to key data about their bodies to ... regimen. Hemoglobin carries oxygen to muscles. ...
Breaking Biology News(10 mins):